210 related articles for article (PubMed ID: 8886211)
1. The appropriate use of NSAIDs in arthritic conditions.
Moskowitz RW
Am J Orthop (Belle Mead NJ); 1996 Sep; 25(9 Suppl):4-6. PubMed ID: 8886211
[TBL] [Abstract][Full Text] [Related]
2. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study.
Singh G; Ramey DR; Morfeld D; Shi H; Hatoum HT; Fries JF
Arch Intern Med; 1996 Jul; 156(14):1530-6. PubMed ID: 8687261
[TBL] [Abstract][Full Text] [Related]
4. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
Hochberg MC
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
[TBL] [Abstract][Full Text] [Related]
5. An evidence-based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis: The Second Canadian Consensus Conference.
Tannenbaum H; Peloso PM; Russell AS; Marlow B
Can J Clin Pharmacol; 2000; 7 Suppl A():4A-16A. PubMed ID: 11011110
[TBL] [Abstract][Full Text] [Related]
6. Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis.
Fries JF; Bruce B
J Rheumatol; 2003 Oct; 30(10):2226-33. PubMed ID: 14528521
[TBL] [Abstract][Full Text] [Related]
7. HZT-501 (DUEXIS(®); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis.
Schiff M; Peura D
Expert Rev Gastroenterol Hepatol; 2012 Feb; 6(1):25-35. PubMed ID: 22149579
[TBL] [Abstract][Full Text] [Related]
8. A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea.
Lee MC; Lee S; Suh DC; Kim J; Kong SX;
Curr Med Res Opin; 2003; 19(7):597-602. PubMed ID: 14606981
[TBL] [Abstract][Full Text] [Related]
9. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients.
Wolfe F; Hawley DJ
J Rheumatol; 2000 Jul; 27(7):1668-73. PubMed ID: 10914849
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with cyclooxygenase-2 inhibitors.
Lanas A
Rheumatology (Oxford); 2002 Apr; 41 Supp 1():16-22; discussion 35-42. PubMed ID: 12173276
[TBL] [Abstract][Full Text] [Related]
11. Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib.
Steinfeld S; Bjørke PA
Rheumatology (Oxford); 2002 Apr; 41 Supp 1():23-7; discussion 35-42. PubMed ID: 12173277
[TBL] [Abstract][Full Text] [Related]
12. [Therapy of non-steroidal antirheumatic drug-induced gastrointestinal lesions with misoprostol].
Bach GL; Stock KP; Hüdepohl M
Z Rheumatol; 1991; 50(3):175-80. PubMed ID: 1927064
[TBL] [Abstract][Full Text] [Related]
13. Double blind, placebo controlled trial on the cytoprotective effect of misoprostol in subjects with rheumatoid arthritis, osteoarthritis and seronegative spondarthropathy on NSAIDs.
Chandrasekaran AN; Sambandam PR; Lal HM; Ramakrishnan S; Porkodi R; Krishnamurthy V; Achutan K
J Assoc Physicians India; 1991 Dec; 39(12):919-21. PubMed ID: 1816217
[TBL] [Abstract][Full Text] [Related]
14. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Maetzel A; Krahn M; Naglie G
Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
[TBL] [Abstract][Full Text] [Related]
15. Misoprostol prevents NSAID-induced gastroduodenal lesions in patients with osteoarthritis and rheumatoid arthritis.
Saggioro A; Alvisi V; Blasi A; Dobrilla G; Fioravanti A; Marcolongo R
Ital J Gastroenterol; 1991; 23(3):119-23. PubMed ID: 1742504
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial.
Simon LS; Hatoum HT; Bittman RM; Archambault WT; Polisson RP
Fam Med; 1996 Mar; 28(3):204-10. PubMed ID: 8900554
[TBL] [Abstract][Full Text] [Related]
17. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy: clinical and economic implications of a single-tablet formulation of diclofenac/misoprostol.
Goldstein JL; Larson LR; Yamashita BD
Am J Manag Care; 1998 May; 4(5):687-97. PubMed ID: 10179922
[TBL] [Abstract][Full Text] [Related]
18. Cost-conscious prescribing of nonsteroidal anti-inflammatory drugs for adults with arthritis. A review and suggestions.
Greene JM; Winickoff RN
Arch Intern Med; 1992 Oct; 152(10):1995-2002. PubMed ID: 1417372
[TBL] [Abstract][Full Text] [Related]
19. Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs.
McCarthy DM
Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):755-73. PubMed ID: 11566039
[TBL] [Abstract][Full Text] [Related]
20. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
Rabeneck L; Goldstein JL; Vu A; Mayne TJ; Rublee DA
Am J Gastroenterol; 2005 May; 100(5):1043-50. PubMed ID: 15842577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
